NCT00573560已完成1 期
A Feasibility Trial to Evaluate the VPD Implant System - Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 14
- 主要终点
- Assessment of safety defined as the successful delivery and deployment of the VPD Implant through 6 month follow up without the occurrence of Major Adverse Cardiac Events (MACE) related to the investigational device.
研究概览
简要总结
The CardioKinetix Ventricular Partitioning Device (VPD) is intended to isolate the malfunctioning portion of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. By isolating the malfunctioning portion of the left ventricle, it is hypothesized that the left ventricle will pump more effectively.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Akinesis or dyskinesis due to myocardial infarction limited to anteroapical region
- •Diagnosis of heart failure for a minimum of 6 months prior to enrollment
- •NYHA Class at time of enrollment, either:
- •NYHA Class III or IV - if predominant during the 3-month period prior to enrollment
- •NYHA Class II - if diagnosed with NYHA Class III or IV during 3-month period prior to enrollment and ≥ 1 hospitalization for heart failure during 12-month period prior to enrollment
- •LVEF ≤ 40% as measured by echocardiography
- •Left ventricle must have appropriate anatomy as measured by Cardiac CT per the VPD Implant sizing criteria described in the device's Instructions For Use
- •Eligible for cardiac surgery
- •Between 18 and 74 years of age (inclusive)
- •Receiving appropriate medical treatment for heart failure according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult during the three months prior to enrollment
- •Female patients with childbearing potential must have a negative pregnancy test (within 7 days of the procedure) and must agree not to attempt to become pregnant during the course of the study
- •Provide written informed consent
- •Agree to the protocol-required follow-up
排除标准
- •Myocardial ischemia requiring PCI or CABG
- •Acute MI (see MI definition) within 60 days of enrollment or patients with suspected evolving MI at time of enrollment
- •Cardiogenic shock within 72 hours of enrollment
- •Revascularization procedure (PCI or CABG) within 60 days of enrollment
- •Patient has received a CRT device within 60 days of enrollment
- •Patient diagnosed with significant valve disease (AI >1+; MR >2+) which may or may not require surgery
- •Patient has received an ICD within 60 days of enrollment
- •Patient has received a pacemaker within 60 days of enrollment
- •History of aborted sudden cardiac death, if patient has not received an ICD and has potentially lethal ventricular arrhythmia, VT or VF
- •Patients with a history or a current diagnosis of either persistent or paroxysmal atrial fibrillation as well as patients who present with a contraindication to oral anticoagulant therapy
- •Aortic valve replacement or repair
- •Resting systolic blood pressure is more than 180 mmHg or less than 90 mmHg
- •Resting heart rate more than 120 bpm
- •Cardiac CT or echocardiographic evidence of thrombus in the left ventricle or left atrium
- •History of bleeding diathesis or a major coagulopathy (i.e. platelet count < 100,000 plts/ml whole blood; PTT or PT > 1.3 times control value)
- •GI bleed requiring transfusion within the past 3 months
- •Patient has suffered a stroke within the past 6 months
- •Evidence of severe calcification in the VPD Implant attachment zone
- •Evidence of a significant sub-aortic obstruction ("left moderator band") in the area of implant
- •History of Kawasaki's disease
- •Patient has received a heart, lung, liver and/or kidney transplant
- •Patient on dialysis or expected to require hemodialysis within 12 months
- •Patient has chronic liver disease
- •Patient has received intracardiac gene therapy or stem cell therapy
- •Creatinine > 2.5mg/dl or impaired renal function that places patient at risk of contrast induced renal failure
- •Hypersensitivity to contrast media
- •Allergy or contraindication to clopidogrel or aspirin
- •Evidence of ongoing infection (fever with temperature > 38°C and/or WBC > 15,000)
- •Co-morbidities associated with a life expectancy of less than 12-months or there are factors making echo and clinical follow-up difficult (no permanent address, etc.)
- •Patient is currently participating in another investigational device or drug research study for which the follow-up period is not complete
结局指标
主要结局
Assessment of safety defined as the successful delivery and deployment of the VPD Implant through 6 month follow up without the occurrence of Major Adverse Cardiac Events (MACE) related to the investigational device.
时间窗: 6 months
次要结局
- Preliminary Effectiveness Measurements at 6 months - Change in LV volume indices (LVESVI, LVEDVI, EF) - Change in 6 minute walk and VO2 max - Cardiovascular mortality and morbidity inclusive of hospitalization for HF, MI and stroke(12 months)
研究者
研究点 (14)
Loading locations...
相似试验
已完成
不适用
DEFLECT I: Keystone Heart Embolic Deflection TrialAortic StenosisNCT01448421Keystone Heart37
已完成
不适用
EVITA: Evaluation of VIP Feature in Pacemaker PatientsArrhythmiaNCT00366158Abbott Medical Devices461
已完成
不适用
China (CN)_Magnetic Resonance Imaging (MRI)_Implantable Cardiac Defibrillator (ICD) [CN_MRI_ICD]TachycardiaNCT03828357Abbott Medical Devices60
已完成
不适用
Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast CancerBreast CancerNCT02521363Memorial Sloan Kettering Cancer Center11
已完成
不适用
Implantable Cardioverter Defibrillator (ICD) Function During Ventricular Assist Device (VAD) ImplantationHeart FailureNCT01576562Virginia Commonwealth University37